ARTICLE | Clinical News
AMT-060 regulatory update
February 3, 2017 12:02 AM UTC
FDA granted breakthrough therapy designation to AMT-060 from uniQure to treat hemophilia B. The company said the designation is based on data from an ongoing, open-label, European Phase I/II trial of ...